Streetbeat News

Price Targets

NUS

DA Davidson analyst Linda Bolton Weiser has maintained a Neutral rating on Nu Skin Enterprises (NYSE:NUS) but has lowered the price target from $29 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:48 pm

OSW

Truist Securities analyst Gregory Miller has reaffirmed a Buy rating on OneSpaWorld Holdings (NASDAQ:OSW) and increased the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:46 pm

APA

Truist Securities analyst Neal Dingmann has reaffirmed a Buy rating on APA Corporation (NASDAQ:APA) and increased the price target from $59 to $61, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:40 pm

NLY

RBC Capital analyst Kenneth Lee has maintained an Outperform rating on Annaly Capital Management (NYSE:NLY) and increased the price target from $18 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:31 pm

AGL

APLT

AXGN

BNZI

MPW

RCAC

STZ

U.S. stocks saw gains with the Dow Jones rising by 50 points. Constellation Brands Inc (NYSE:STZ) reported Q3 earnings with higher-than-expected EPS but lower sales, leading to a reduced FY24 EPS outlook. AxoGen, Inc. (NASDAQ:AXGN) shares surged on positive preliminary revenue and CEO retirement news. Banzai International, Inc. (NASDAQ:BNZI) spiked after announcing a letter of intent to acquire IGLeads. Revelstone Capital Acquisition Corp. (NASDAQ:RCAC) saw a jump in shares after cancelling a special meeting for a business combination. Applied Therapeutics, Inc. (NASDAQ:APLT), agilon health, inc. (NYSE:AGL), and Medical Properties Trust, Inc. (NYSE:MPW) experienced significant share price drops due to negative clinical trial results, lowered financial outlook, and exposure reduction plans, respectively. Crude oil prices increased by 2.3%, while gold saw a slight decline.

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 7:30 pm

FUSN

Raymond James analyst Rahul Sarugaser has reaffirmed a Strong Buy rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and increased the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:30 pm

AGNC

RBC Capital analyst Kenneth Lee has maintained an Outperform rating on AGNC Investment (NASDAQ:AGNC) and increased the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:28 pm

SNOW

Snowflake Inc (NYSE:SNOW) stock is trading higher after RBC Capital analyst Matthew Hedberg initiated coverage with an Outperform rating and a $230 price target. Hedberg is optimistic about Snowflake's long-term growth, citing improving cloud optimization trends, rapid adoption of Snowpark, and potential with new GenAI offerings. He believes Snowflake is well-positioned for cross-selling into ML and GenAI use cases and expects a more material impact on results in CY25 and beyond. The analyst also views management as best-in-class and projects Q4 revenue and EPS slightly above consensus.

Portfolio Pulse from Anusuya Lahiri

January 05, 2024 | 7:10 pm

TW

Tradeweb Markets (NASDAQ:TW) has been analyzed by 10 analysts in the last three months, with a diverse range of perspectives. The recent assessments show a shift towards a more bullish outlook, with the average 12-month price target raised to $96.5, up from the previous $90.10. Analysts from firms like Raymond James, UBS, Morgan Stanley, Rosenblatt, JP Morgan, Deutsche Bank, Barclays, and Piper Sandler have raised their price targets for TW, indicating a positive sentiment towards the company's performance and market position.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:01 pm

SHAK

Analyst ratings for Shake Shack (NYSE:SHAK) show a mix of opinions, with 9 analysts offering varied ratings over the last quarter. The 12-month price targets have an average of $71.11, with a high of $85.00 and a low of $59.00, reflecting a 1.51% decrease from the previous average. Recent actions include ratings and target adjustments by analysts from firms such as Oppenheimer, HSBC, Raymond James, Truist Securities, Stifel, Barclays, Deutsche Bank, and Morgan Stanley. Shake Shack's financials indicate a solid revenue growth rate of 21.24%, an exceptional net margin of 2.76%, but lower ROE and ROA compared to industry averages, and a healthy debt-to-equity ratio of 1.84.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm